Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP

Robert Keers; Rudolf Uher; Bhanu Gupta; Marcella Rietschel; Thomas G. Schulze; Joanna Hauser; Maria Skibinska; Neven Henigsberg; Petra Kalember; Wolfgang Maier; Astrid Zobel; Ole Mors; Ann S. Kristensen; Dejan Kozel; Caterina Giovannini; Julien Mendlewicz; Sudhir Kumar; Peter McGuffin; Anne E. Farmer; Katherine J. Aitchison

doi:10.1016/j.jad.2010.06.011

Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP

Robert Keers, Rudolf Uher, Bhanu Gupta, Marcella Rietschel, Thomas G. Schulze, Joanna Hauser, Maria Skibinska, Neven Henigsberg, Petra Kalember, Wolfgang Maier, Astrid Zobel, Ole Mors, Ann S. Kristensen, Dejan Kozel, Caterina Giovannini, Julien Mendlewicz, Sudhir Kumar, Peter McGuffin, Anne E. Farmer, Katherine J. Aitchison

Résultat de recherche: Article › examen par les pairs

29 Citations (Scopus)

Résumé

Background: The occurrence of stressful life events (SLEs) has been shown to predict response to antidepressants; however, results are inconsistent. There is some evidence to suggest that SLEs prior to treatment are associated with greater cognitive symptoms at baseline and may therefore predict changes in these symptoms specifically. Methods: GENDEP, a prospective part-randomised pharmacogenomics trial, collected longitudinal data on the symptoms of patients with major depression treated with either a selective serotonin reuptake inhibitor (SSRI, escitalopram) or a tricyclic antidepressant (TCA, nortriptyline). Data on life events experienced in the 6 months preceding treatment measured using the List of Threatening Experiences Questionnaire (LTE-Q) were available for 728 participants. Results: Both the occurrence and number of SLEs were associated with greater cognitive but not mood or neurovegetative symptoms prior to treatment. Those who reported SLEs also experienced a greater decline in cognitive symptoms during treatment with escitalopram, but not with nortriptyline. Limitations: Life events were measured retrospectively using a self-report checklist and are therefore subject to a number of biases especially in the context of depressive illness. Conclusions: These findings are in line with cognitive theories of depression and suggest that symptomatic heterogeneity may have contributed to inconsistencies in studies reported to date. Our results also tentatively suggest a clinically relevant drug specific effect of SLEs. Specifically, those reporting stress may benefit more from treatment with SSRIs than TCAs.

Langue d'origine	English
Pages (de-à)	337-342
Nombre de pages	6
Journal	Journal of Affective Disorders
Volume	127
Numéro de publication	1-3
DOI	https://doi.org/10.1016/j.jad.2010.06.011
Statut de publication	Published - déc. 2010
Publié à l'externe	Oui

Note bibliographique

Funding Information:
The GENDEP project was funded by the European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. Robert Keers is funded by a Medical Research Council (MRC) PhD Studentship to the MRC SGDP Centre at the Institute of Psychiatry, King's College London. Lundbeck provided both nortriptyline and escitalopram free of charge for the GENDEP study. GlaxoSmithKline, the Medical Research Council, and the Biomedical Research Center for Mental Health at the Institute of Psychiatry and South London and Maudsley NHS Foundation Trust (funded by the United Kingdom National Institute for Health Research of the Department of Health) contributed to the funding of the sample collection at the Institute of Psychiatry, London, through add-on projects or latterly staff funding. The sponsors had no role in the design and conduct of the study, in data collection, analysis, interpretation or writing the report.

ASJC Scopus Subject Areas

Clinical Psychology
Psychiatry and Mental health

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1016/j.jad.2010.06.011

Autres fichiers et liens

Citer

Keers, R., Uher, R., Gupta, B., Rietschel, M., Schulze, T. G., Hauser, J., Skibinska, M., Henigsberg, N., Kalember, P., Maier, W., Zobel, A., Mors, O., Kristensen, A. S., Kozel, D., Giovannini, C., Mendlewicz, J., Kumar, S., McGuffin, P., Farmer, A. E., & Aitchison, K. J. (2010). Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. Journal of Affective Disorders, 127(1-3), 337-342. https://doi.org/10.1016/j.jad.2010.06.011

Keers, R, Uher, R, Gupta, B, Rietschel, M, Schulze, TG, Hauser, J, Skibinska, M, Henigsberg, N, Kalember, P, Maier, W, Zobel, A, Mors, O, Kristensen, AS, Kozel, D, Giovannini, C, Mendlewicz, J, Kumar, S, McGuffin, P, Farmer, AE & Aitchison, KJ 2010, 'Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP', Journal of Affective Disorders, vol. 127, n° 1-3, pp. 337-342. https://doi.org/10.1016/j.jad.2010.06.011

@article{578771a10b6f47e581471d3018a985c9,

title = "Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP",

abstract = "Background: The occurrence of stressful life events (SLEs) has been shown to predict response to antidepressants; however, results are inconsistent. There is some evidence to suggest that SLEs prior to treatment are associated with greater cognitive symptoms at baseline and may therefore predict changes in these symptoms specifically. Methods: GENDEP, a prospective part-randomised pharmacogenomics trial, collected longitudinal data on the symptoms of patients with major depression treated with either a selective serotonin reuptake inhibitor (SSRI, escitalopram) or a tricyclic antidepressant (TCA, nortriptyline). Data on life events experienced in the 6 months preceding treatment measured using the List of Threatening Experiences Questionnaire (LTE-Q) were available for 728 participants. Results: Both the occurrence and number of SLEs were associated with greater cognitive but not mood or neurovegetative symptoms prior to treatment. Those who reported SLEs also experienced a greater decline in cognitive symptoms during treatment with escitalopram, but not with nortriptyline. Limitations: Life events were measured retrospectively using a self-report checklist and are therefore subject to a number of biases especially in the context of depressive illness. Conclusions: These findings are in line with cognitive theories of depression and suggest that symptomatic heterogeneity may have contributed to inconsistencies in studies reported to date. Our results also tentatively suggest a clinically relevant drug specific effect of SLEs. Specifically, those reporting stress may benefit more from treatment with SSRIs than TCAs.",

author = "Robert Keers and Rudolf Uher and Bhanu Gupta and Marcella Rietschel and Schulze, {Thomas G.} and Joanna Hauser and Maria Skibinska and Neven Henigsberg and Petra Kalember and Wolfgang Maier and Astrid Zobel and Ole Mors and Kristensen, {Ann S.} and Dejan Kozel and Caterina Giovannini and Julien Mendlewicz and Sudhir Kumar and Peter McGuffin and Farmer, {Anne E.} and Aitchison, {Katherine J.}",

note = "Funding Information: The GENDEP project was funded by the European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. Robert Keers is funded by a Medical Research Council (MRC) PhD Studentship to the MRC SGDP Centre at the Institute of Psychiatry, King's College London. Lundbeck provided both nortriptyline and escitalopram free of charge for the GENDEP study. GlaxoSmithKline, the Medical Research Council, and the Biomedical Research Center for Mental Health at the Institute of Psychiatry and South London and Maudsley NHS Foundation Trust (funded by the United Kingdom National Institute for Health Research of the Department of Health) contributed to the funding of the sample collection at the Institute of Psychiatry, London, through add-on projects or latterly staff funding. The sponsors had no role in the design and conduct of the study, in data collection, analysis, interpretation or writing the report. ",

year = "2010",

month = dec,

doi = "10.1016/j.jad.2010.06.011",

language = "English",

volume = "127",

pages = "337--342",

journal = "Journal of Affective Disorders",

issn = "0165-0327",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP

AU - Keers, Robert

AU - Uher, Rudolf

AU - Gupta, Bhanu

AU - Rietschel, Marcella

AU - Schulze, Thomas G.

AU - Hauser, Joanna

AU - Skibinska, Maria

AU - Henigsberg, Neven

AU - Kalember, Petra

AU - Maier, Wolfgang

AU - Zobel, Astrid

AU - Mors, Ole

AU - Kristensen, Ann S.

AU - Kozel, Dejan

AU - Giovannini, Caterina

AU - Mendlewicz, Julien

AU - Kumar, Sudhir

AU - McGuffin, Peter

AU - Farmer, Anne E.

AU - Aitchison, Katherine J.

N1 - Funding Information: The GENDEP project was funded by the European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. Robert Keers is funded by a Medical Research Council (MRC) PhD Studentship to the MRC SGDP Centre at the Institute of Psychiatry, King's College London. Lundbeck provided both nortriptyline and escitalopram free of charge for the GENDEP study. GlaxoSmithKline, the Medical Research Council, and the Biomedical Research Center for Mental Health at the Institute of Psychiatry and South London and Maudsley NHS Foundation Trust (funded by the United Kingdom National Institute for Health Research of the Department of Health) contributed to the funding of the sample collection at the Institute of Psychiatry, London, through add-on projects or latterly staff funding. The sponsors had no role in the design and conduct of the study, in data collection, analysis, interpretation or writing the report.

PY - 2010/12

Y1 - 2010/12

N2 - Background: The occurrence of stressful life events (SLEs) has been shown to predict response to antidepressants; however, results are inconsistent. There is some evidence to suggest that SLEs prior to treatment are associated with greater cognitive symptoms at baseline and may therefore predict changes in these symptoms specifically. Methods: GENDEP, a prospective part-randomised pharmacogenomics trial, collected longitudinal data on the symptoms of patients with major depression treated with either a selective serotonin reuptake inhibitor (SSRI, escitalopram) or a tricyclic antidepressant (TCA, nortriptyline). Data on life events experienced in the 6 months preceding treatment measured using the List of Threatening Experiences Questionnaire (LTE-Q) were available for 728 participants. Results: Both the occurrence and number of SLEs were associated with greater cognitive but not mood or neurovegetative symptoms prior to treatment. Those who reported SLEs also experienced a greater decline in cognitive symptoms during treatment with escitalopram, but not with nortriptyline. Limitations: Life events were measured retrospectively using a self-report checklist and are therefore subject to a number of biases especially in the context of depressive illness. Conclusions: These findings are in line with cognitive theories of depression and suggest that symptomatic heterogeneity may have contributed to inconsistencies in studies reported to date. Our results also tentatively suggest a clinically relevant drug specific effect of SLEs. Specifically, those reporting stress may benefit more from treatment with SSRIs than TCAs.

AB - Background: The occurrence of stressful life events (SLEs) has been shown to predict response to antidepressants; however, results are inconsistent. There is some evidence to suggest that SLEs prior to treatment are associated with greater cognitive symptoms at baseline and may therefore predict changes in these symptoms specifically. Methods: GENDEP, a prospective part-randomised pharmacogenomics trial, collected longitudinal data on the symptoms of patients with major depression treated with either a selective serotonin reuptake inhibitor (SSRI, escitalopram) or a tricyclic antidepressant (TCA, nortriptyline). Data on life events experienced in the 6 months preceding treatment measured using the List of Threatening Experiences Questionnaire (LTE-Q) were available for 728 participants. Results: Both the occurrence and number of SLEs were associated with greater cognitive but not mood or neurovegetative symptoms prior to treatment. Those who reported SLEs also experienced a greater decline in cognitive symptoms during treatment with escitalopram, but not with nortriptyline. Limitations: Life events were measured retrospectively using a self-report checklist and are therefore subject to a number of biases especially in the context of depressive illness. Conclusions: These findings are in line with cognitive theories of depression and suggest that symptomatic heterogeneity may have contributed to inconsistencies in studies reported to date. Our results also tentatively suggest a clinically relevant drug specific effect of SLEs. Specifically, those reporting stress may benefit more from treatment with SSRIs than TCAs.

UR - http://www.scopus.com/inward/record.url?scp=78149361750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149361750&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2010.06.011

DO - 10.1016/j.jad.2010.06.011

M3 - Article

C2 - 20609482

AN - SCOPUS:78149361750

SN - 0165-0327

VL - 127

SP - 337

EP - 342

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

IS - 1-3

ER -

Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer